Novartis: Macular Degeneration trials

The registry lists 81 Macular Degeneration studies with Novartis as lead sponsor. 1 are open to participants now and 41 have results posted.

Phase 1 5Phase 2 12Phase 3 24Phase 4 18No phase 25(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationRecruitingNCT07441642Phase 2
• Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial KitCompletedNCT05282004Phase 3Results posted
• Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT05269966Phase 4Results posted
• Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled SyringeCompletedNCT05161806Phase 3Results posted
• Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular DegenerationCompletedNCT04864834Phase 3Results posted
• Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedNCT04774926Phase 4Results posted
• Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
• An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedNCT04597632Phase 3Results posted
• Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedNCT04264819Phase 3Results posted
• A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular DegenerationCompletedNCT04239027Phase 3Results posted
• Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular DegenerationCompletedNCT04047472Phase 3Results posted
• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
• Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMDCompletedNCT03954626Phase 3Results posted
• Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular DegenerationCompletedNCT03930641Phase 3Results posted
• Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular EdemaCompletedNCT03927690Phase 2Results posted
• Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF InjectionsTerminatedNCT03710564Phase 3Results posted
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMDCompletedNCT03386474Phase 3Results posted
• Head to Head Study of Anti-VEGF Treatment.CompletedNCT02577107Phase 4Results posted
• LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular DegenerationCompletedNCT02355028Phase 2Results posted
• Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02257632Phase 4Results posted
• Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMDCompletedNCT02161575Phase 4Results posted
• Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.CompletedNCT02140411Phase 4Results posted
• A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD PatientsCompletedNCT02130024Phase 4Results posted
• Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment PhaseTerminatedNCT02032173Phase 3Results posted
• Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected EyeCompletedNCT01986907Phase 4Results posted
• Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)CompletedNCT01972789Phase 4Results posted
• Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMDCompletedNCT01958918Phase 4Results posted
• Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDCompletedNCT01948830Phase 3Results posted
• Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)CompletedNCT01846273Phase 4Results posted
• Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular DegenerationCompletedNCT01780935Phase 3Results posted
• Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)CompletedNCT01775124Phase 4Results posted
• Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVOCompletedNCT01580020Phase 4Results posted
• Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)CompletedNCT01527500Phase 2Results posted
• Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)CompletedNCT01148511Phase 4Results posted
• The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular DegenerationTerminatedNCT00857259Phase 2Results posted
• Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedNCT00674323Phase 4Results posted
• Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationCompletedNCT00436553Phase 3Results posted
• Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT00433017Phase 2/3Results posted
• SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationCompletedNCT00331864Phase 3Results posted
• Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00284089Phase 1/2Results posted
• Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)CompletedNCT00275821Phase 3Results posted
• A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal PegaptanibCompletedNCT00242580Phase 3Results posted
• A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT06699914
• Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)CompletedNCT06184360
• Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-upCompletedNCT06178770
• Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE StudyCompletedNCT06021366
• A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in IndiaCompletedNCT05834075
• Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world SettingTerminatedNCT05266495
• A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationCompletedNCT05230537Phase 2
• Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)CompletedNCT05146687
• Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical PracticeTerminatedNCT05112835
• Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)CompletedNCT05111743
• Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)CompletedNCT05110209
• Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)CompletedNCT05082415
• Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services ProgramCompletedNCT05066685
• Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of BroluciumabCompletedNCT05037396
• Regulatory Post-Marketing Surveillance Study for BrolucizumabCompletedNCT04985487
• Russian Registry of Patients With nAMDTerminatedNCT04935411
• Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved IndicationsCompletedNCT04847895
• Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in PortugalTerminatedNCT04764656
• Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)WithdrawnNCT04697953Phase 3
• A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF InjectionsCompletedNCT04662944
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema PatientsCompletedNCT04635800Phase 1
• A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMDCompletedNCT04632056
• Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular EdemaCompletedNCT04543331
• Canadian Treat and Extend Analysis Trial With RanibizumabCompletedNCT02103738
• Mobile Clinic - a Cross-sectional Epidemiological SurveyCompletedNCT02055612
• A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology ClinicsTerminatedNCT02005133
• Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).TerminatedNCT01624636Phase 2
• A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)CompletedNCT01542866Not applicable
• Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)CompletedNCT01535950Phase 2
• Observe the Effectiveness and Safety of Ranibizumab in Real Life SettingCompletedNCT01318941
• Intravitreal LFG316 in Patients With Advanced Age-related Macular DegenerationCompletedNCT01255462Phase 1
• Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular DegenerationCompletedNCT00967213Phase 3
• Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) PatientsCompletedNCT00826371Phase 3
• Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00504959Phase 4
• Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular DegenerationCompletedNCT00503022Phase 1
• EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)CompletedNCT00470678Phase 3
• Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular DegenerationCompletedNCT00288561Phase 2
• Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00138632Phase 1/2
• Photodynamic Therapy in Occult-Only Lesions (POOL)CompletedNCT00135837Phase 4